The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
OptiMAL® has raised the Company's profile with new connections being made with significant prospective clients, further enhancing our strategy of penetration into adjacent markets including Veterinary Medicine, Diagnostics and Research Antibodies.
The critical thing in my view is the fact that if the validation pays off, they will jointly publish the results. The number one cancer research agency in the world, publishing and independently verifying that your world leading, first of kind technology is working. There’s no price that can be put on that and I would imagine fusion would be snapped up for 100 multiples of this price is that happens.
Https://fusionantibodies.com/careers/facilities-manager/
https://fusionantibodies.com/careers/protein-characterisation-senior-scientist/
https://fusionantibodies.com/careers/laboratory-technician/
https://fusionantibodies.com/careers/production-scientist/
https://fusionantibodies.com/careers/team-leader-antibody-engineering/
Https://www.linkedin.com/posts/eurofinsdiscovery_optimize-your-antibody-therapy-for-function-ugcPost-7119737993317289984-rW8V?utm_source=share&utm_medium=member_ios
Eurofins promoting their services
There’s always the possibility of eurofins snapping them up. They’re already marketed as part of their discovery pathway:
https://cf-ecom.eurofinsdiscoveryservices.com/wp-content/uploads/2022/11/Eurofins-Discovery_IPAFushion-Flyer_21310_111522.pdf
Interesting the glossy version of the annual report published details the list of top shareholders (different to their website). Some big institutional players in there I’m surprised they didn’t TR1 those as they’re all new as far as I can see and they’re up there %wise. Page 38
https://www.fusionantibodies-ir.com/docs/librariesprovider21/archive/reports/ar2023.pdf
It now has a cash runway of at least 15 months from today and it is possible that the signs of this turnaround working could be seen within the next few months. Given its depressed share price, this effectively represents a special situation that is potentially highly geared to the potential recovery in revenues.
: Fusion’s market capitalisation is £3.4m and the company currently has c.£1m in
cash, so its EV is in the region of £2.4m. While we acknowledge that the company has to
succeed in its turnaround to regain shareholder support, we consider that this figure does
not to ascribe any value to Fusion’s potentially valuable and class-leading technologies,
that could be worth a multiple of this figure.
Allenby capital new research note out today.
https://www.allenbycapital.com/client/fusion-antibodies/
Hilarious! Trigger the stoplosses and scrape some much needed volume in perhaps!
Hopefully this is the tail of the negativity - all the challenging stuff should be priced in as it’s been known since March. The trajectory still feels upwards to me with a more stable cost base.